Technical Analysis for WVE - WAVE Life Sciences Ltd.

Grade Last Price % Change Price Change
C 5.73 -2.05% -0.12
WVE closed up 1.04 percent on Wednesday, May 8, 2024, on 83 percent of normal volume. It was able to find support at its 50 day moving average.
Earnings due: May 9
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Up

Date Alert Name Type % Chg
50 DMA Support Bullish -2.05%
Wide Bands Range Expansion -2.05%
50 DMA Support Bullish -1.04%
180 Bullish Setup Bullish Swing Setup -1.04%
Wide Bands Range Expansion -1.04%
MACD Bullish Centerline Cross Bullish -0.35%
Wide Bands Range Expansion -0.35%
Pocket Pivot Bullish Swing Setup -6.68%
Stochastic Reached Overbought Strength -6.68%
Wide Bands Range Expansion -6.68%

   Recent Intraday Alerts

Alert Time
50 DMA Support 9 minutes ago
Gapped Down (Full) 19 minutes ago
10 DMA Support 19 minutes ago
50 DMA Resistance 19 minutes ago
Down 5% 19 minutes ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

WAVE Life Sciences Ltd. Description

WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Rare Diseases Medical Genetics Dysfunction Inflammatory Bowel Disease Dystrophy Muscular Dystrophy Huntington's Disease Duchenne Muscular Dystrophy Genodermatoses Duchenne Epidermolysis Bullosa Genetic Genealogy Cytoskeleton Dystrophin

Is WVE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.6699
52 Week Low 3.1501
Average Volume 880,742
200-Day Moving Average 5.11
50-Day Moving Average 5.71
20-Day Moving Average 5.32
10-Day Moving Average 5.43
Average True Range 0.38
RSI (14) 56.71
ADX 23.11
+DI 30.83
-DI 22.54
Chandelier Exit (Long, 3 ATRs) 5.25
Chandelier Exit (Short, 3 ATRs) 5.77
Upper Bollinger Bands 6.32
Lower Bollinger Band 4.33
Percent B (%b) 0.77
BandWidth 37.39
MACD Line 0.05
MACD Signal Line -0.06
MACD Histogram 0.1133
Fundamentals Value
Market Cap 696.96 Million
Num Shares 119 Million
EPS -0.84
Price-to-Earnings (P/E) Ratio -6.96
Price-to-Sales 5.45
Price-to-Book 10.21
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.25
Resistance 3 (R3) 6.22 6.07 6.18
Resistance 2 (R2) 6.07 5.97 6.08 6.16
Resistance 1 (R1) 5.96 5.90 6.01 5.98 6.14
Pivot Point 5.80 5.80 5.83 5.81 5.80
Support 1 (S1) 5.69 5.70 5.75 5.72 5.56
Support 2 (S2) 5.54 5.64 5.55 5.54
Support 3 (S3) 5.43 5.54 5.52
Support 4 (S4) 5.45